• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>DRS

DRS

  1. All
  2. 3rd Party
  3. Investing
  1. EndoGastric Solutions Announces 12-month Data Validating Hiatal Hernia Repair Prior to Transoral Incisionless Fundoplication (TIF®) as a Durable GERD Treatment Option

    EndoGastric Solutions Announces 12-month Data Validating Hiatal Hernia Repair Prior to Transoral Incisionless Fundoplication (TIF®) as a Durable GERD Treatment Option

  2. WindMIL Therapeutics Announces New Cancer Immunotherapy Approach Based on Marrow-Infiltrating Lymphocytes

    WindMIL Therapeutics Announces New Cancer Immunotherapy Approach Based on Marrow-Infiltrating Lymphocytes

12345

©2017 Morningstar Advisor. All right reserved.